HK1004484A1 - Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis. - Google Patents

Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis.

Info

Publication number
HK1004484A1
HK1004484A1 HK98103632A HK98103632A HK1004484A1 HK 1004484 A1 HK1004484 A1 HK 1004484A1 HK 98103632 A HK98103632 A HK 98103632A HK 98103632 A HK98103632 A HK 98103632A HK 1004484 A1 HK1004484 A1 HK 1004484A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pyrimidine nucleotide
nucleotide precursors
inflammatory hepatitis
hepatitis
Prior art date
Application number
HK98103632A
Other languages
English (en)
Inventor
Reid Warren Von Borstel
Michael Kevin Bamat
Bradley M Hiltbrand
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of HK1004484A1 publication Critical patent/HK1004484A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK98103632A 1992-12-08 1998-04-29 Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis. HK1004484A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98773092A 1992-12-08 1992-12-08
PCT/US1993/011531 WO1994013687A1 (en) 1992-12-08 1993-12-01 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis

Publications (1)

Publication Number Publication Date
HK1004484A1 true HK1004484A1 (en) 1998-11-27

Family

ID=25533509

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103632A HK1004484A1 (en) 1992-12-08 1998-04-29 Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis.

Country Status (15)

Country Link
EP (2) EP0679160B1 (ja)
JP (3) JPH08503699A (ja)
KR (1) KR100315890B1 (ja)
CN (2) CN1089239C (ja)
AT (1) ATE282627T1 (ja)
AU (2) AU5730594A (ja)
CA (2) CA2150940C (ja)
DE (1) DE69333699T2 (ja)
ES (1) ES2229212T3 (ja)
HK (1) HK1004484A1 (ja)
IL (1) IL107900A (ja)
MX (1) MX9307765A (ja)
PT (1) PT679160E (ja)
WO (1) WO1994013687A1 (ja)
ZA (1) ZA939208B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173017B1 (en) 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US6329350B1 (en) 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
CN101066276A (zh) 1994-07-01 2007-11-07 威尔斯塔特医疗公司 用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
US20020006913A1 (en) 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
SE521031C2 (sv) 1999-05-05 2003-09-23 Srinivas Uppugunduri Nya specifika inhibitorer av akut och kronisk inflammation
EP1402892A4 (en) * 2001-06-11 2006-11-08 Kyowa Hakko Kogyo Kk ANTI-INFLAMMATORY AND ANTITUSSIVE COMPOSITIONS
WO2016008603A1 (en) * 2014-07-16 2016-01-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling
EP3002010A1 (en) * 2014-09-30 2016-04-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling
WO2018038599A1 (en) * 2016-08-23 2018-03-01 N.V. Nutricia Product and method for increasing uridine concentration in blood plasma
CN118175986A (zh) 2021-10-07 2024-06-11 雅玛山酱油株式会社 皮肤外用组合物及其利用、以及皮肤外用组合物原料
CN114469981A (zh) * 2021-12-16 2022-05-13 中国科学院动物研究所 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1297398A (ja) * 1969-08-06 1972-11-22
US3868451A (en) * 1971-03-30 1975-02-25 Abbott Lab Adenosine-5{40 -esters in treating angina pectoris
JPS6037183B2 (ja) * 1977-03-24 1985-08-24 日本冶金工業株式会社 耐食性にすぐれた高力オ−ステナイトステンレス鋼
JPS6037182B2 (ja) * 1977-03-24 1985-08-24 日本冶金工業株式会社 耐食性にすぐれた高強度オ−ステナイトステンレス鋼
JPS5585659A (en) * 1978-12-25 1980-06-27 Daido Steel Co Ltd Free-cutting nonmagnetic high-manganese steel
JPS58126956A (ja) * 1982-01-22 1983-07-28 Nippon Steel Corp プレス加工性の優れた高強度薄鋼板
JPS6054374B2 (ja) * 1982-04-21 1985-11-29 新日本製鐵株式会社 オ−ステナイト鋼板および鋼帯の製造方法
DE3481191D1 (de) * 1983-07-20 1990-03-08 Teijin Ltd Antineoplastisches mittel.
JPS60174797A (ja) * 1984-02-21 1985-09-09 Funai Corp Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
KR890002033B1 (ko) * 1985-08-31 1989-06-08 한국과학기술원 최저온용 합금 및 그 제조방법
DE3855513T2 (de) * 1987-10-28 1997-01-09 Pro Neuron Inc Acyl deoxyribonukleosid-derivate und deren verwendungen
JP2894610B2 (ja) * 1987-10-28 1999-05-24 プロ−ニューロン,インコーポレーテッド アシル化ウリジンおよびシチジンならびにその使用
US4874602A (en) * 1988-02-22 1989-10-17 Paul Calabresi Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia using benzylacyclouridine
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
JP2529605B2 (ja) * 1989-10-23 1996-08-28 株式会社大塚製薬工場 免疫賦活剤
JPH03169815A (ja) * 1989-11-29 1991-07-23 Nippon Mining Co Ltd 肝臓障害予防及び治療剤
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives

Also Published As

Publication number Publication date
AU732120B2 (en) 2001-04-12
DE69333699D1 (de) 2004-12-23
AU5730594A (en) 1994-07-04
CN1211089C (zh) 2005-07-20
CA2588495C (en) 2009-11-17
KR100315890B1 (ko) 2002-06-27
CA2150940A1 (en) 1994-06-23
IL107900A0 (en) 1994-05-30
DE69333699T2 (de) 2006-07-27
CA2150940C (en) 2007-08-21
EP0679160A4 (en) 1997-06-11
JP2007332144A (ja) 2007-12-27
EP1486210A1 (en) 2004-12-15
ES2229212T3 (es) 2005-04-16
IL107900A (en) 1999-12-22
ZA939208B (en) 1994-08-08
EP0679160B1 (en) 2004-11-17
CN1309970A (zh) 2001-08-29
MX9307765A (es) 1994-06-30
AU7881398A (en) 1998-10-08
CA2588495A1 (en) 1994-06-23
JPH08503699A (ja) 1996-04-23
KR950704342A (ko) 1995-11-20
WO1994013687A1 (en) 1994-06-23
CN1095268A (zh) 1994-11-23
EP0679160A1 (en) 1995-11-02
JP2005162757A (ja) 2005-06-23
ATE282627T1 (de) 2004-12-15
PT679160E (pt) 2005-02-28
CN1089239C (zh) 2002-08-21

Similar Documents

Publication Publication Date Title
MX9700109A (es) Precursores nucleotidos de pirimidina para el tratamiento de inflamaciones sistemicas y hepatitis inflamatoria.
IL107900A0 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
DK0805683T3 (da) 5-fluor-2',3'-umættet-pyrimidinnukleosider
PL319944A1 (en) Nucleosides of modified sugars and their use in synthesis of oligonucleotides
AU6081294A (en) Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
NO20011493L (no) Kjemoterapi av cancer med acetyldinalin i kombinasjon med gemcitabin, capecitabin eller cisplatin
DK0653439T3 (da) Stabiliserede oligonukleotider og anvendelse heraf
EP0939637A4 (en) PROCESS FOR TREATING SINUSITY WITH TRIPHOSPHATE URIDINES AND RELATED COMPOUNDS
FI932870A (fi) 2'-deoxi-2'2'-difluor-(4-substituerad pyrimidin)nukleosider med virus-och cancerhaemmande aktivitet, samt mellanprodukter
DK1491201T3 (da) Fremgangsmåder til reduktion af toksicitet af 5-fluoruracil med acylerede pyrimidinnukleosider
FI913236A (fi) 9-purinylfosfonsyraderivat.
ES2138969T3 (es) Combinacion de nucleosidos antivirales.
ATA10689A (de) Didesoxydehydrocarbocyclische nucleoside und deren verwendung
ZA898567B (en) Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine,uridine and guanosine derivatives
DK630589D0 (da) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor-sammensaetning
WO1996032403A3 (de) Neue cytosin- und cytidinderivate
HUP0002249A3 (en) Use of pyrimidine and triazine derivatives for producing pharmaceutical compositions useful for treating cancer
AU5312586A (en) Composition and method for treatment of tumors with UDPG
ITMI912224A0 (it) Impiego di composti adenosinici nel trattamento dell'ischemia
EP0458519A3 (en) Synthesis of nucleotide and nucleoside derivatives
DE69617031T2 (de) Pyrimidin nukleosid derivate
NZ239422A (en) Phospholipid derivatives of nucleosides and antiviral compositions
ZA899510B (en) 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition
AU2002320811A1 (en) Pyrimidine Nucleotide Precursors for Treatment of Systemic Inflammation and Inflammatory Hepatitis
MX9709749A (es) Metodo para reducir la toxicidad de agentes quimioterapeuticos y antivirales con nucleosidos de pirimidina acilados.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091201